At a Glance
- Company: Congruence Therapeutics; Ono Pharma
- Location: Montreal, Canada; Osaka, Japan
- Headline figures: Undisclosed upfront + milestones + royalties
- Focus area: Small molecule modulators via Revenir engine
- Next steps: Development candidates for new programs
What happened?
Congruence Therapeutics and Ono Pharmaceutical expanded their multi-target research collaboration on 2 March 2026, adding two new programs in neurology and immunology. Congruence will use its Revenir computational platform to discover small molecule modulators and advance them to development candidate stage; Ono holds exclusive worldwide option rights.
Why does it matter?
Revenir captures protein biophysical states to design allosteric modulators for challenging targets; expansion beyond oncology validates platform across high-value areas lacking precision therapies. Builds Ono’s pipeline while providing Congruence R&D funding amid clinical advances in obesity/Parkinson’s.
Who’s behind it?
Congruence Therapeutics leverages AI-driven protein dynamics; Ono Pharma gains early access to candidates. CSO Sharath Hegde and Ono’s Seishi Katsumata highlighted mutual trust from oncology collaboration.
How was it achieved?
New targets are clinically validated; Congruence leads discovery to candidate nomination using Revenir’s conformational analysis. Ono reimburses costs and funds milestones tied to progress.
What’s next?
Congruence nominates candidates for existing programs (GBA Parkinson’s, A1AT); Ono exercises options post-review. Expansion supports Congruence’s wholly owned phase 1 MC4R obesity trial.
What are people saying?
CSO Hegde: “Testament to… contributions… trust with Ono.” Ono’s Katsumata: “Expanding beyond oncology… innovative new medicines.”